[1] Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124.
[2] Takiar V, Voong KR, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, et al. A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Pract Radiat Oncol. 2015; 5(3): 169-76
[3] Wilkinson DA, Kolar M, Fleming PA, Singh AD. Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (<or=5 mm) choroidal melanoma lesions. Br J Radiol. 2008; 81: 784–789.
[4] Thomson RM, Furutani KM, Kaulich TW, Mourtada F, Rivard MJ, Soares CG, Vanneste FM, Melhus CS. AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221. Med Phys. 2019 Dec 28. doi: 10.1002/mp.13996.
[5] Jampol LM, Moy CS, Murray TG et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002; 109: 2197-2206
[6] Perez BA, Mettu P, Vajzovic L et al. Uveal melanoma treated with iodine-125 episcleral plaque: An analysis of dose on disease control and visual outcomes. Int J Radiat Oncol Biol Phys 2014; 89: 127-136.
[7] Correa R, Pera J, Gómez J et al. (125)I episcleral plaque brachytherapy in the treatment of choroidal melanoma: a single-institution experience in Spain. Brachytherapy 2009;
8: 290-296.
[8] Miguel D, de Frutos-Baraja JM, López-Lara F et al. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I.
J Contemp Brachytherapy. 2018 Aug;10(4):337-346.
[9] Dendale R, Lumbroso- Le Rouic L, Noel G, et al: Proton beam radiotherapy for uveal melanoma: results of Curie Institut- Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys 2006;65: 780– 787.
[10] Caujolle JP, Mammar H, Chamorey E, Pinon F, Herault J, Gastaud P: Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years’ experience. Int J Radiat Oncol Biol Phys 2010;78:98– 103.
[11] Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM: Evidence- based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002;120: 1665– 1671.
[12] Browne, A.W., Dandapani, S.V., Jennelle, R. et al. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. Brachytherapy 2015, 14, 718–725.
[13] Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013; 86(1):18-26.
[14] Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Cassoux N, Dendale R, Mazal A, et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol. 2012; 49: 41-57.
[15] Melia BM, Abramson DH, Albert DM et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16 Ophthalmology. 2001 Feb;108(2):348-66.
[16] Aziz HA, Singh N, Bena J et al. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool. JAMA Ophthalmol. 2016 Jun 1;134(6):615-20.
[17] Le BHA, Kim JW, Deng H et al. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review. Brachytherapy. 2018 Nov - Dec;17(6):981-989.
[18] Francis JH, Cohen GN, Marr BP, Wolden SL, McCormick B, et al. (106) Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. Brachytherapy. 2014;13(6):584-90
[19] Espensen CA, Appelt AL, Fog LS et. al. Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas. Cancers (Basel). 2019 Aug 6;11(8).
[20] Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas. Twenty years’ experience. Am J Clin Oncol 1987; 10:146-151.
[21] Seregard S, aft Trampe E, Lax I, Kock E, Lundell G. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand 1997; 75:11-16
[22] Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63:385-391.